Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389779 · ClinicalTrials.gov registry record · Phase 3
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 849
- Enrollment target
NCT00389779 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 849 participants.
The verdict
NCT00389779, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 849 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo- and active-controlled study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is effective in reducing systolic and diastolic hypertension despite treatment with full doses of three or more antihypertensive drugs, including a diuretic. Subjects will be randomized to darusentan (optimized dose), an active comparator, or placebo, administered orally. The treatment period for this trial is 14 weeks.
Interventions
- DRUG Guanfacine
- DRUG Darusentan
- DRUG Darusentan Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 849 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389779
The ClinicalTrials.gov registry entry for NCT00389779 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 849 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Guanfacine is the first listed.
NCT00389779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00389779 about?
NCT00389779 is a clinical study titled "DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension". This is a randomized, double-blind, placebo- and active-controlled study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to d...
What is the current status of trial NCT00389779?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 849 participants. The study started on 2006-09. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00389779?
The interventions under investigation include: Guanfacine (DRUG), Darusentan (DRUG), Darusentan Placebo (DRUG).
Who is sponsoring clinical trial NCT00389779?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.